Search clinical trials for: inactive powder

Total 57293 results

New York Medical College

Recruiting

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL)

Hodgkin Lymphoma | Non-hodgkin Lymphoma

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (TOASTIT)

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Rhabdomyosarcoma | Refractory Rhabdomyosarcoma | Recurrent Colon Carcinoma | Recurrent Gastric Carcinoma | Recurrent Rectal Carcinoma | Refractory Sarcoma | Refractory Ovarian Carcinoma | Resectable... and other conditions

United States
Jonsson Comprehensive Cancer Center
Society of Nuclear Medecine and Molecular Imaging

Recruiting

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Breast Carcinoma | Gastric Carcinoma | Head and Neck Carcinoma | Lung Carcinoma | Ovarian Carcinoma | Colon Carcinoma | Esophageal Carcinoma | Kidney Carcinoma | Pancreatic Carcinoma | Uterine Corpus Cancer | Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Memorial Sloan Kettering Cancer Center

Completed

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Rectal Cancer

United States
Jonsson Comprehensive Cancer Center

Withdrawn

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8
St. Jude Children's Research Hospital
Baylor College of Medicine; Gateway for Cancer Research

Active, not recruiting

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Acute Lymphoblastic Leukemia

United States, Canada
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Withdrawn

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); National Institute of General Medical Sciences... and other collaborators

Completed

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
University Hospital, Tours
University Hospital, Rouen; Central Hospital, Nancy, France; Poitiers University... and other collaborators

Completed

Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (TRULIGHT)

HIV

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Lymphoma

Lymphoma

United States
Stanford University

Terminated

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Lymphoma, Non-Hodgkin | Diffuse Large B-cell Lymphoma (DLBCL) | Lymphoma, B-cell | Malignant Lymphoma, Non-Hodgkin

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Non-Hodgkin Lymphoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Adult Rhabdomyosarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Pleomorphic Rhabdomyosarcoma | Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Uma Borate

Suspended

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
National Cancer Institute (NCI)
The Lymphoma Academic Research Organisation

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

HIV Infection | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin... and other conditions

United States, France
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage III Uterine Corpus... and other conditions

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Amyloidosis | Plasma Cell Myeloma

United States
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
Fred Hutchinson Cancer Center
Pfizer

Completed

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center

Terminated

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Burkitt Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Acute Leukemia in Remission | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia and other conditions

United States
Fred Hutchinson Cancer Center

Terminated

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Glioblastoma | Gliosarcoma

United States
Mehrdad Abedi, MD
Amgen

Completed

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Stage IV Adult Lymphoblastic Lymphoma | Contiguous Stage II Adult Lymphoblastic Lymphoma | Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Stage I Adult Lymphoblastic Lymphoma | Stage III Adult Lymphoblastic Lymphoma | Untreated Adult Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
Centre Hospitalier Universitaire de Nice

Completed

MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers (MELA)

Healthy

France
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

Leukemia

United States, Canada, Netherlands, Puerto Rico, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Sarcoma

Canada, United States, Australia, Puerto Rico
University of Washington

Recruiting

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Locally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
University of Oxford
Bill and Melinda Gates Foundation; Department for International Development... and other collaborators

Recruiting

Randomised Evaluation of COVID-19 Therapy (RECOVERY)

Severe Acute Respiratory Syndrome

Ghana, Indonesia, Nepal, South Africa, United Kingdom, Vietnam, India
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Varian Medical Systems

Suspended

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage III Lung Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, Switzerland
St. Jude Children's Research Hospital
Cookies for Kids' Cancer; CURE Childhood Cancer, Inc.

Active, not recruiting

Therapy for Children With Advanced Stage Neuroblastoma

Neuroblastoma

United States
Fred Hutchinson Cancer Center

Terminated

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | KSHV-associated Multicentric Castleman Disease

Uganda
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States, Canada

Search clinical trials for: inactive powder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations